Freire M.P.,Hospital Control Infection and Infectious Diseases Service |
Pierrotti L.C.,Hospital Control Infection and Infectious Diseases Service |
Filho H.H.C.,University of Sao Paulo |
Ibrahim K.Y.,Hospital Control Infection and Infectious Diseases Service |
And 7 more authors.
European Journal of Clinical Microbiology and Infectious Diseases | Year: 2014
Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae (KPC-Kp) is an emergent pathogen in healthcare-associated infections (HAIs). The aim of this study was to describe HAIs due to KPC-Kp, as well as identify mortality risk factors in cancer patients. In patients diagnosed with HAIs due to KPC-Kp between January 2009 and July 2013, we evaluated only the first infection episode of each patient, analyzing mortality separately for patients treated for ≥48 h with at least one antimicrobial agent proven to display in vitro activity against KPC-Kp. We evaluated variables related to the malignancy, the severity and characteristics of the HAI, and the antimicrobial therapy. We identified 83 HAIs due to KPC-Kp. The 30-day mortality was 57.8 % for all infections and 72.7 % for bacteremic infections. Of the 83 patients, 60 patients received ≥48 h of appropriate treatment and 44 (53 %) developed bacteremia. Ten patients (12 %) were neutropenic at HAI diagnosis and 33 (39.8 %) had infection at the tumor site. The most common HAI was urinary tract infection, seen in 26 patients (31.3 %), followed by primary bloodstream infection, seen in 24 patients (28.9 %). Forty-four patients (73.3 %) received combination antimicrobial therapy, most often including polymyxin (68.3 %). Risk factors for 30-day mortality are high sequential organ failure assessment (SOFA) score, need for intensive care stay at diagnosis of infection, and acute kidney injury; the removal of invasive devices related to infection and treatment with effective antibiotics for KPC-Kp are protective factors. In cancer patients, high mortality is associated with HAI due to KPC-Kp and mortality risk factors are more often related to acute infection than to the underlying disease. © 2014, Springer-Verlag Berlin Heidelberg.
Gastrointestinal stromal tumor: Analysis of 146 cases of the center of reference of the National Cancer Institute - INCA [Tumor estromal gastrointestinal: Análise de 146 casos do centro de referência do Instituto Nacional do Câncer - INCA]
Linhares E.,FACS |
Goncalves R.,GIST Group |
Valadao M.,GIST Group |
Vilhena B.,Service of Clinical Oncology |
And 6 more authors.
Revista do Colegio Brasileiro de Cirurgioes | Year: 2011
Objective: To evaluate the treatment of GIST in INCA. Methods: We conducted a retrospective analysis of all cases of GIST treated at INCA in the period from 1997 to 2009. Results: We analyzed 146 patients with a mean age of 44.5 years and female predominance. The main symptom was abdominal pain. We observed the occurrence of a second primary tumor in 22% of cases and 92% of the immunohistochemistry exams were positive for CD117. The most frequent location was in the stomach and the high-risk group was predominant. Surgery was considered R0 (extensive) in 70% of the cases and the main sites of metastases were liver and peritoneum. Overall survival in two and five years was, respectively, 86% and 59%. There was a significant difference between overall survival (p = 0.29) of the high-risk group versus the other. Conclusion: Our patients presented mainly in the form of highrisk disease, with obvious impact on survival. The use of imatinib improved survival of patients with recurrent and metastatic disease. We should study its use in the setting of adjuvant and neoadjuvant therapy to improve results of the high risk group. The creation of reference centers is a need for the study of rare diseases.